Pharmaceuticals Global On demand · 24-48h

Global TCM Granules in Prescriptions Market Strategic Research Report

Global TCM Granules in Prescriptions Market Strategic Resear…
$3,500 USD
Market Research Reports
Strategic Research Report
Global TCM Granules in Prescriptions Market
$14.9B2025
12.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Uniform Formula Granules, Compound Formula Granules

By Application: Children, Adults, Elderly

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Jiangyin Tianjiang(China), Tsumura & Co.(Japan), Tianjin Hongri(China), Sanjiu Medical(China), Sichuan Neo-Green(China), PuraPharm(Hong Kong, China), Jilin Aodong(China), China Shineway Pharmaceutical(China), Anhui Jiren(China), Guangdong Yifang(China), Jiangxi Baishen(China), Heilongjiang Shuanglanxing(China), Zhejiang Jingyuetang(China)

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 105 pages
Market size 2025
$14.9B
Billion USD
Forecast CAGR
12.8%
2025-2032
Forecast 2032
$34.6B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global TCM Granules in Prescriptions market size is predicted to grow from US$ 14,903 million in 2025 to US$ 35,055 million in 2032; it is expected to grow at a CAGR of 12.8% from 2026 to 2032.

TCM Granules in Prescriptions refer to standardized granulated formulations produced from single-herb decoction pieces through modern pharmaceutical processes such as extraction, concentration, separation, drying, and granulation. Under the guidance of traditional Chinese medicine (TCM) theory, these granules are prescribed and compounded by physicians and administered through oral dissolution. Combining the therapeutic philosophy of TCM with industrial-level quality control, they offer advantages such as no decoction requirement, precise dosage, portability, and consistent quality, making them a key vehicle for the modernization and standardization of TCM, and a substitute for traditional herbal decoctions.The average gross profit margin of this product is 55%.

Driven by the “Healthy China” strategy and continuous policy support for TCM revitalization, TCM granules are entering a new phase of full market liberalization after the pilot period. The removal of regulatory restrictions and the establishment of unified national standards have significantly expanded market capacity and improved industry standardization. Increasing demand from healthcare institutions for standardized and traceable medicines further accelerates hospital penetration. In addition, aging populations and rising chronic disease prevalence are expanding long-term demand, reinforcing the role of TCM granules in primary care and chronic disease management.With market liberalization, the number of competitors has increased rapidly, breaking previous licensing barriers and intensifying competition under stricter regulatory frameworks. Enhanced national standards for active ingredient content, quality control, and testing systems have raised production costs and compressed margins. Transitional inconsistencies in standard implementation and product registration may lead to short-term supply disruptions. Moreover, volatility in upstream raw material supply and pricing further increases operational uncertainty, potentially reshaping industry concentration.On the demand side, TCM granules are expanding beyond traditional TCM hospitals into general hospitals, primary care institutions, and digital healthcare platforms. Patients’ preference for convenience and standardized treatment is accelerating the substitution of traditional decoctions. Meanwhile, trends toward personalized medicine and chronic disease management are fostering integration with digital healthcare solutions, enabling a shift from product-based to service-oriented models. Growing global acceptance of TCM also opens opportunities for international expansion and export markets.The core raw materials for TCM granules are Chinese medicinal herbs and decoction pieces, whose quality directly determines product efficacy and consistency. Strengthened national standards require higher levels of authenticity, active ingredient control, and traceability, driving upstream cultivation and processing toward standardization and scale. However, herb production remains subject to climate, geographic distribution, and cyclical supply-demand dynamics, resulting in significant price volatility. As a result, supply chain integration, origin-based sourcing, and long-term procurement strategies are becoming critical competitive factors for manufacturers.

This report presents a comprehensive overview of the global TCM Granules in Prescriptions market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Uniform Formula Granules
  • Compound Formula Granules

Segment by Therapeutic Area

  • Chronic Diseases
  • Respiratory Care
  • Digestive System
  • Others

Segment by Application

  • Hospitals
  • Retail Pharmacies
  • Other

Segment by Application

  • Children
  • Adults
  • Elderly

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global TCM Granules in Prescriptions market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Children, Adults, Elderly evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global TCM Granules in Prescriptions Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 12.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$14.9B
2025
Forecast
$34.6B
2032
CAGR
12.8%
2025–2032
Regions
5
global
Key companies
Jiangyin Tianjiang(China)Tsumura & Co.(Japan)Tianjin Hongri(China)Sanjiu Medical(China)Sichuan Neo-Green(China)PuraPharm(Hong KongChina)Jilin Aodong(China)
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Uniform Formula GranulesCompound Formula Granules
By Application
ChildrenAdultsElderly

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Uniform Formula Granules
  • 3.1.3 Compound Formula Granules
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Children
  • 4.1.3 Adults
  • 4.1.4 Elderly
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Jiangyin Tianjiang(China)
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Tsumura & Co.(Japan)
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Tianjin Hongri(China)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Sanjiu Medical(China)
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Sichuan Neo-Green(China)
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 PuraPharm(Hong Kong, China)
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Jilin Aodong(China)
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 China Shineway Pharmaceutical(China)
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Anhui Jiren(China)
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Guangdong Yifang(China)
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Jiangxi Baishen(China)
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Heilongjiang Shuanglanxing(China)
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Zhejiang Jingyuetang(China)
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global TCM Granules in Prescriptions market size?
The global TCM Granules in Prescriptions market is estimated at US$ 14.9 billion in 2025 (base year) and is projected to reach US$ 35.05 billion by 2032.
What growth rate is expected for the TCM Granules in Prescriptions market through 2032?
The market is expected to grow at a CAGR of 12.8% from 2026 to 2032, expanding from US$ 14.9 billion in 2025 to US$ 35.05 billion in 2032, roughly 2.4 times its base-year value.
How is TCM Granules in Prescriptions defined?
TCM Granules in Prescriptions refer to standardized granulated formulations produced from single-herb decoction pieces through modern pharmaceutical processes such as extraction, concentration, separation, drying, and granulation. Under the guidance of traditional Chinese medicine (TCM) theory, these granules are prescribed and compounded by physicians and administered through oral dissolution.
What are the main segments of the TCM Granules in Prescriptions market by type?
By type, the market is segmented into Uniform Formula Granules and Compound Formula Granules.
Which applications drive demand in the TCM Granules in Prescriptions market?
Key applications covered include Children, Adults and Elderly.
Who are the key players in the TCM Granules in Prescriptions market?
Key players profiled include Jiangyin Tianjiang(China), Tsumura & Co.(Japan), Tianjin Hongri(China), Sanjiu Medical(China), Sichuan Neo-Green(China), PuraPharm(Hong Kong, China), Jilin Aodong(China) and China Shineway Pharmaceutical(China), among 13 companies covered in total.
Which regions and countries are covered for TCM Granules in Prescriptions?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the TCM Granules in Prescriptions market?
Driven by the “Healthy China” strategy and continuous policy support for TCM revitalization, TCM granules are entering a new phase of full market liberalization after the pilot period.
What challenges does the TCM Granules in Prescriptions market face?
In addition, aging populations and rising chronic disease prevalence are expanding long-term demand, reinforcing the role of TCM granules in primary care and chronic disease management.With market liberalization, the number of competitors has increased rapidly, breaking previous licensing barriers and intensifying competition under stricter regulatory frameworks.
Who should buy the TCM Granules in Prescriptions market report?
The report is intended for manufacturers and solution providers, distributors and end users in Children, Adults and Elderly, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the TCM Granules in Prescriptions market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.